{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:21:51Z","timestamp":1787066511764,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Epileptologica"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>NR2F1<\/jats:italic>\n                      mutations are associated with Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS). Although\u2009~\u200946.7% of BBSOAS patients present with epilepsy, which is always drug-resistant and associated with higher rates of behavioral and cognitive problems, the treatment and outcomes of\n                      <jats:italic>NR2F1<\/jats:italic>\n                      -related epilepsy have rarely been described. Here, we present new cases of BBSOAS-related epilepsy and summarize all previously reported cases to explore the effective treatment for this type of epilepsy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We identified six new Chinese cases of BBSOAS with epilepsy. Five different de novo heterozygous\n                      <jats:italic>NR2F1<\/jats:italic>\n                      mutations were identified in these cases, including two novel mutations c.365G\u2009&gt;\u2009T, p.Cys122Phe and c.449G\u2009&gt;\u2009T, p.Gly150Val. By combining the six cases and 14 previously reported cases, we analyzed the characteristics and treatment outcomes of\n                      <jats:italic>NR2F1<\/jats:italic>\n                      -related epilepsy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve of the 20 patients (60%) had infantile epileptic spasms, while the other patients had generalized tonic\/tonic-clonic, focal, myoclonic, absence, or unclassified seizures. Several anti-seizure medications, steroids, and a ketogenic diet were administered in these cases. However, seizures were controlled in only 50% of previously reported cases, while all of the six new cases became seizure-free after perampanel as an add-on treatment. The average time from the addition of perampanel to seizure control was 7.33\u2009\u00b1\u20094.59\u00a0months (range, 1\u201312\u00a0months). The median time to seizure freedom was 14\u00a0months (1\u201332\u00a0months,\u2009&gt;\u200919\u00a0months in 3 cases). The average dosage of perampanel needed for epilepsy control was 0.22\u2009\u00b1\u20090.17\u00a0mg\/kg per day.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In this paper, we comprehensively summarized the clinical characteristics, treatments and outcomes of\n                      <jats:italic>NR2F1<\/jats:italic>\n                      -related epilepsy for the first time. Perampanel exhibits dramatic efficacy for\n                      <jats:italic>NR2F1<\/jats:italic>\n                      -related epilepsy. This will help optimize the treatment of this type of epilepsy and provide clues for its pathogenic mechanisms. The two novel mutations expand the genotype spectrum of this disease.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42494-023-00145-0","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T21:02:37Z","timestamp":1706043757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effective treatment of NR2F1-related epilepsy with perampanel"],"prefix":"10.1186","volume":"6","author":[{"given":"Xiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5179-9807","authenticated-orcid":false,"given":"Yuwu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"issue":"2","key":"145_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ajhg.2014.01.002","volume":"94","author":"DG Bosch","year":"2014","unstructured":"Bosch DG, Boonstra FN, Gonzaga-Jauregui C, Xu M, de Ligt J, Jhangiani S, et al. NR2F1 mutations cause optic atrophy with intellectual disability. Am J Hum Genet. 2014;94(2):303\u20139.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"145_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00439-015-1553-6","volume":"134","author":"N Hino-Fukuyo","year":"2015","unstructured":"Hino-Fukuyo N, Kikuchi A, Arai-Ichinoi N, Niihori T, Sato R, Suzuki T, et al. Genomic analysis identifies candidate pathogenic variants in 9 of 18 patients with unexplained West syndrome. Hum Genet. 2015;134(6):649\u201358.","journal-title":"Hum Genet"},{"issue":"11","key":"145_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/gim.2016.18","volume":"18","author":"CA Chen","year":"2016","unstructured":"Chen CA, Bosch DG, Cho MT, Rosenfeld JA, Shinawi M, Lewis RA, et al. The expanding clinical phenotype of Bosch-Boonstra-Schaaf optic atrophy syndrome: 20 new cases and possible genotype-phenotype correlations. Genet Med. 2016;18(11):1143\u201350.","journal-title":"Genet Med"},{"issue":"4","key":"145_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s10038-017-0398-3","volume":"63","author":"E Mart\u00edn-Hern\u00e1ndez","year":"2018","unstructured":"Mart\u00edn-Hern\u00e1ndez E, Rodr\u00edguez-Garc\u00eda ME, Chen CA, Cotrina-Vinagre FJ, Carnicero-Rodr\u00edguez P, Bellusci M, et al. Mitochondrial involvement in a Bosch-Boonstra-Schaaf optic atrophy syndrome patient with a novel de novo NR2F1 gene mutation. J Hum Genet. 2018;63(4):525\u20138.","journal-title":"J Hum Genet"},{"issue":"1","key":"145_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ajmg.a.61409","volume":"182","author":"EK Bojanek","year":"2020","unstructured":"Bojanek EK, Mosconi MW, Guter S, Betancur C, Macmillan C, Cook EH. Clinical and neurocognitive issues associated with Bosch-Boonstra-Schaaf optic atrophy syndrome: A case study. Am J Med Genet A. 2020;182(1):213\u20138.","journal-title":"Am J Med Genet A"},{"issue":"10","key":"145_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2020.104019","volume":"63","author":"S Walsh","year":"2020","unstructured":"Walsh S, G\u00f6sswein SS, Rump A, von der Hagen M, Hackmann K, Schr\u00f6ck E, et al. Novel dominant-negative NR2F1 frameshift mutation and a phenotypic expansion of the Bosch-Boonstra-Schaaf optic atrophy syndrome. Eur J Med Genet. 2020;63(10): 104019.","journal-title":"Eur J Med Genet"},{"key":"145_CR7","doi-asserted-by":"crossref","unstructured":"Jurkute N, Bertacchi M, Arno G, Tocco C, Kim US, Kruszewski AM, et al. Pathogenic NR2F1 variants cause a developmental ocular phenotype recapitulated in a mutant mouse model. Brain Commun. 2021;3(3):fcab162.","DOI":"10.1093\/braincomms\/fcab162"},{"issue":"13","key":"145_CR8","doi-asserted-by":"publisher","first-page":"e104163","DOI":"10.15252\/embj.2019104163","volume":"39","author":"M Bertacchi","year":"2020","unstructured":"Bertacchi M, Romano AL, Loubat A, Tran Mau-Them F, Willems M, Faivre L, et al. NR2F1 regulates regional progenitor dynamics in the mouse neocortex and cortical gyrification in BBSOAS patients. EMBO J. 2020;39(13):e104163.","journal-title":"EMBO J"},{"key":"145_CR9","doi-asserted-by":"crossref","unstructured":"Cardoso C, Boys A, Parrini E, Mignon-Ravix C, McMahon JM, Khantane S, et al. Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion. Neurology. 2009;72(9):784\u201392.","DOI":"10.1212\/01.wnl.0000336339.08878.2d"},{"issue":"2","key":"145_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/cge.12636","volume":"89","author":"S Dimassi","year":"2016","unstructured":"Dimassi S, Labalme A, Ville D, Calender A, Mignot C, Boutry-Kryza N, et al. Whole-exome sequencing improves the diagnosis yield in sporadic infantile spasm syndrome. Clin Genet. 2016;89(2):198\u2013204.","journal-title":"Clin Genet"},{"key":"145_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.seizure.2017.06.018","volume":"50","author":"N Hino-Fukuyo","year":"2017","unstructured":"Hino-Fukuyo N, Kikuchi A, Yokoyama H, Iinuma K, Hirose M, Haginoya K, et al. Long-term outcome of a 26-year-old woman with West syndrome and an nuclear receptor subfamily 2 group F member 1 gene (NR2F1) mutation. Seizure. 2017;50:144\u20136.","journal-title":"Seizure"},{"issue":"6","key":"145_CR12","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a002162","volume":"3","author":"C Kaiwar","year":"2017","unstructured":"Kaiwar C, Zimmermann MT, Ferber MJ, Niu Z, Urrutia RA, Klee EW, et al. Novel NR2F1 variants likely disrupt DNA binding: molecular modeling in two cases, review of published cases, genotype-phenotype correlation, and phenotypic expansion of the Bosch-Boonstra-Schaaf optic atrophy syndrome. Cold Spring Harb Mol Case Stud. 2017;3(6): a002162.","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"145_CR13","doi-asserted-by":"crossref","unstructured":"Gazdagh G, Mawby R, Self JE, Baralle D. Deciphering Developmental Disorders Study. A severe case of Bosch-Boonstra-Schaaf optic atrophy syndrome with a novel description of coloboma and septo-optic dysplasia, owing to a start codon variant in the NR2F1 gene. Am J Med Genet A. 2022;188(3):900\u2013906.","DOI":"10.1002\/ajmg.a.62569"},{"key":"145_CR14","doi-asserted-by":"crossref","unstructured":"uskaitis CJ, Mytinger JR, Baumer FM, Zhang B, Liu S, Samanta D, et al. Pediatric Epilepsy Research Consortium. Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms. Neurology. 2022;99(22):e2494-e2503.","DOI":"10.1212\/WNL.0000000000201232"},{"issue":"3","key":"145_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/08830738211073400","volume":"37","author":"KG Knupp","year":"2022","unstructured":"Knupp KG, Coryell J, Singh RK, Gaillard WD, Shellhaas RA, Koh S, et al. Comparison of Cosyntropin, Vigabatrin, and Combination Therapy in New-Onset Infantile Spasms in a Prospective Randomized Trial. J Child Neurol. 2022;37(3):186\u201393.","journal-title":"J Child Neurol"},{"key":"145_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.eplepsyres.2018.06.013","volume":"145","author":"A Ko","year":"2018","unstructured":"Ko A, Youn SE, Chung HJ, Kim SH, Lee JS, Kim HD, et al. Vigabatrin and high-dose prednisolone therapy for patients with West syndrome. Epilepsy Res. 2018;145:127\u201333.","journal-title":"Epilepsy Res"},{"issue":"6229","key":"145_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/340163a0","volume":"340","author":"LH Wang","year":"1989","unstructured":"Wang LH, Tsai SY, Cook RG, Beattie WG, Tsai MJ, O\u2019Malley BW. COUP transcription factor is a member of the steroid receptor superfamily. Nature. 1989;340(6229):163\u20136.","journal-title":"Nature"},{"key":"145_CR18","first-page":"207","volume":"1","author":"LH Wang","year":"1991","unstructured":"Wang LH, Ing NH, Tsai SY, O\u2019Malley BW, Tsai MJ. The COUP-TFs compose a family of functionally related transcription factors. Gene Expr. 1991;1:207\u201316.","journal-title":"Gene Expr"},{"issue":"1","key":"145_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1006\/geno.1995.1237","volume":"29","author":"Y Qiu","year":"1995","unstructured":"Qiu Y, Krishnan V, Zeng Z, Gilbert DJ, Copeland NG, Gibson L, et al. Isolation, characterization and chromosomal localization of mouse and human COUP-TF I and II genes. Genomics. 1995;29(1):240\u20136.","journal-title":"Genomics"},{"issue":"8","key":"145_CR20","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3390\/cells11081260","volume":"11","author":"M Bertacchi","year":"2022","unstructured":"Bertacchi M, Tocco C, Schaaf CP, Studer M. Pathophysiological Heterogeneity of the BBSOA Neurodevelopmental Syndrome. Cells. 2022;11(8):1260.","journal-title":"Cells"},{"issue":"12","key":"145_CR21","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1523\/JNEUROSCI.6580-10.2011","volume":"31","author":"S Lodato","year":"2011","unstructured":"Lodato S, Tomassy GS, De Leonibus E, Uzcategui YG, Andolfi G, Armentano M, et al. Loss of COUP-TFI alters the balance between caudal ganglionic eminence- and medial ganglionic eminence-derived cortical interneurons and results in resistance to epilepsy. J Neurosci. 2011;31(12):4650\u201362.","journal-title":"J Neurosci"},{"issue":"11","key":"145_CR22","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.1093\/cercor\/bhaa137","volume":"30","author":"I Del Pino","year":"2020","unstructured":"Del Pino I, Tocco C, Magrinelli E, Marcantoni A, Ferraguto C, Tomagra G, et al. COUP-TFI\/Nr2f1 Orchestrates Intrinsic Neuronal Activity during Development of the Somatosensory Cortex. Cereb Cortex. 2020;30(11):5667\u201385.","journal-title":"Cereb Cortex"},{"issue":"9","key":"145_CR23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s11626-016-0056-7","volume":"52","author":"Y Teratani-Ota","year":"2016","unstructured":"Teratani-Ota Y, Yamamizu K, Piao Y, Sharova L, Amano M, Yu H, et al. Induction of specific neuron types by overexpression of single transcription factors. In Vitro Cell Dev Biol Anim. 2016;52(9):961\u201373.","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"3","key":"145_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.03.085","volume":"31","author":"K Zhang","year":"2020","unstructured":"Zhang K, Yu F, Zhu J, Han S, Chen J, Wu X, et al. Imbalance of Excitatory\/Inhibitory Neuron Differentiation in Neurodevelopmental Disorders with an NR2F1 Point Mutation. Cell Rep. 2020;31(3): 107521.","journal-title":"Cell Rep"},{"issue":"4","key":"145_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.neuint.2012.02.035","volume":"61","author":"L Ceolin","year":"2012","unstructured":"Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int. 2012;61(4):517\u201322.","journal-title":"Neurochem Int"},{"issue":"4","key":"145_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2014.891580","volume":"9","author":"T Hanada","year":"2014","unstructured":"Hanada T. The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov. 2014;9(4):449\u201358.","journal-title":"Expert Opin Drug Discov"},{"issue":"15","key":"145_CR27","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2165\/00003495-200767150-00008","volume":"67","author":"KA Lyseng-Williamson","year":"2007","unstructured":"Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007;67(15):2231\u201356.","journal-title":"Drugs"}],"container-title":["Acta Epileptologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-023-00145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42494-023-00145-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-023-00145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T21:04:44Z","timestamp":1706043884000},"score":1,"resource":{"primary":{"URL":"https:\/\/aepi.biomedcentral.com\/articles\/10.1186\/s42494-023-00145-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["145"],"URL":"https:\/\/doi.org\/10.1186\/s42494-023-00145-0","relation":{},"ISSN":["2096-9384","2524-4434"],"issn-type":[{"value":"2096-9384","type":"print"},{"value":"2524-4434","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"30 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Research Ethics Committee of Peking University First Hospital in China (Ethical approval number:2005[004]). Written informed consent was obtained from participants and their parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author Yuwu Jiang is the member of the Editorial Board for Acta Epileptologica, who was not involved in the journal\u2019s review of, or decisions related to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}